Neumora Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations and Communications. Please go ahead.

Good morning, and thank you for joining UMORA Therapeutics' fourth quarter and full year 2024 Financial Results Conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me on the call are Numora's Chief Executive Officer, Paul Burns, President, Josh Pinto, Chief Operating and Development Officer, Bill Arora, and Chief Financial Officer, Mike Milligan. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details. With that, I'll now turn the call over to Paul.

Thanks, Helen. Good morning, everyone, and thank you for joining us to review our fourth quarter and full year 2024 financial results and business update. As you may know, I've recently taken over as CEO And I'm pleased to be here with all of you today. I have been fortunate to have had multiple experiences leading teams to drive the successful development and approval of medicines. And I believe Numora has the potential to achieve this outcome as well. The first two months of 2025 have been productive for the company. And we believe that we are poised to make a difference for the millions of people living with brain diseases. as we strive to improve on the limitations associated with current treatment options. We have built an industry-leading pipeline of seven programs, all targeting novel mechanisms of action with best-in-class pharmacology. We are in a strong financial position, providing us the flexibility to advance several clinical and preclinical programs, adapt and follow the science, and ultimately deliver medicines to patients who urgently need new treatment options We are also fortunate to have assembled a deep roster of neuroscience drug developers and business leaders that we believe can drive our mission to deliver medicines to patients suffering from brain disease. I will now turn the call over to Josh Pinto, who has been newly appointed president of Numora after serving as our chief financial officer for the last four years to review the pipeline updates. Josh. Thank you, Paul.